These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 36306479)

  • 1. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study.
    de Castro G; Kudaba I; Wu YL; Lopes G; Kowalski DM; Turna HZ; Caglevic C; Zhang L; Karaszewska B; Laktionov KK; Srimuninnimit V; Bondarenko I; Kubota K; Mukherjee R; Lin J; Souza F; Mok TSK; Cho BC
    J Clin Oncol; 2023 Apr; 41(11):1986-1991. PubMed ID: 36306479
    [No Abstract]   [Full Text] [Related]  

  • 2. Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study.
    Garassino MC; Gadgeel S; Speranza G; Felip E; Esteban E; Dómine M; Hochmair MJ; Powell SF; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Hui R; Garon EB; Kurata T; Gray JE; Schwarzenberger P; Jensen E; Pietanza MC; Rodríguez-Abreu D
    J Clin Oncol; 2023 Apr; 41(11):1992-1998. PubMed ID: 36809080
    [No Abstract]   [Full Text] [Related]  

  • 3. Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China Study.
    Wu YL; Zhang L; Fan Y; Zhou J; Zhang L; Zhou Q; Li W; Hu C; Chen G; Zhang X; Zhou C; Dang T; Sadowski S; Kush DA; Zhou Y; Li B; Mok T
    Int J Cancer; 2021 May; 148(9):2313-2320. PubMed ID: 33231285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.
    Mok TSK; Wu YL; Kudaba I; Kowalski DM; Cho BC; Turna HZ; Castro G; Srimuninnimit V; Laktionov KK; Bondarenko I; Kubota K; Lubiniecki GM; Zhang J; Kush D; Lopes G;
    Lancet; 2019 May; 393(10183):1819-1830. PubMed ID: 30955977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up.
    Gadgeel SM; Rodríguez-Abreu D; Halmos B; Garassino MC; Kurata T; Cheng Y; Jensen E; Shamoun M; Rajagopalan K; Paz-Ares L
    J Thorac Oncol; 2024 Aug; 19(8):1228-1241. PubMed ID: 38642841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.
    Novello S; Kowalski DM; Luft A; Gümüş M; Vicente D; Mazières J; Rodríguez-Cid J; Tafreshi A; Cheng Y; Lee KH; Golf A; Sugawara S; Robinson AG; Halmos B; Jensen E; Schwarzenberger P; Pietanza MC; Paz-Ares L
    J Clin Oncol; 2023 Apr; 41(11):1999-2006. PubMed ID: 36735893
    [No Abstract]   [Full Text] [Related]  

  • 7. First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
    Satouchi M; Nosaki K; Takahashi T; Nakagawa K; Aoe K; Kurata T; Sekine A; Horiike A; Fukuhara T; Sugawara S; Umemura S; Saka H; Okamoto I; Yamamoto N; Sakai H; Kishi K; Katakami N; Horinouchi H; Hida T; Okamoto H; Atagi S; Ohira T; Han SR; Noguchi K; Ebiana V; Hotta K
    Cancer Sci; 2020 Dec; 111(12):4480-4489. PubMed ID: 32926507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized Phase III Study of Pembrolizumab Versus Pembrolizumab-Carboplatin-Pemetrexed for Locally Advanced or Metastatic Nonsquamous Non-small-cell Lung Cancer with PD-L1 50% or more (LAPLACE-50): Study Protocol.
    Kogure Y; Hashimoto H; Oki M
    Clin Lung Cancer; 2021 Nov; 22(6):e921-e924. PubMed ID: 34053861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
    Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
    Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
    Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
    Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Vandormael K; Riccio A; Yang J; Pietanza MC; Brahmer JR
    J Clin Oncol; 2019 Mar; 37(7):537-546. PubMed ID: 30620668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
    Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G
    Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study.
    Boyer M; Şendur MAN; Rodríguez-Abreu D; Park K; Lee DH; Çiçin I; Yumuk PF; Orlandi FJ; Leal TA; Molinier O; Soparattanapaisarn N; Langleben A; Califano R; Medgyasszay B; Hsia TC; Otterson GA; Xu L; Piperdi B; Samkari A; Reck M;
    J Clin Oncol; 2021 Jul; 39(21):2327-2338. PubMed ID: 33513313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study.
    Herbst RS; Garon EB; Kim DW; Cho BC; Perez-Gracia JL; Han JY; Arvis CD; Majem M; Forster MD; Monnet I; Novello S; Szalai Z; Gubens MA; Su WC; Ceresoli GL; Samkari A; Jensen EH; Lubiniecki GM; Baas P
    J Clin Oncol; 2020 May; 38(14):1580-1590. PubMed ID: 32078391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC.
    Awad MM; Gadgeel SM; Borghaei H; Patnaik A; Yang JC; Powell SF; Gentzler RD; Martins RG; Stevenson JP; Altan M; Jalal SI; Panwalkar A; Gubens M; Sequist LV; Saraf S; Zhao B; Piperdi B; Langer CJ
    J Thorac Oncol; 2021 Jan; 16(1):162-168. PubMed ID: 33069888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC.
    Herbst RS; Garon EB; Kim DW; Cho BC; Gervais R; Perez-Gracia JL; Han JY; Majem M; Forster MD; Monnet I; Novello S; Gubens MA; Boyer M; Su WC; Samkari A; Jensen EH; Kobie J; Piperdi B; Baas P
    J Thorac Oncol; 2021 Oct; 16(10):1718-1732. PubMed ID: 34048946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
    Satouchi M; Nosaki K; Takahashi T; Nakagawa K; Aoe K; Kurata T; Sekine A; Horiike A; Fukuhara T; Sugawara S; Umemura S; Saka H; Okamoto I; Yamamoto N; Sakai H; Kishi K; Katakami N; Horinouchi H; Hida T; Okamoto H; Atagi S; Ohira T; Rong Han S; Noguchi K; Ebiana V; Hotta K
    Cancer Sci; 2021 Dec; 112(12):5000-5010. PubMed ID: 34543477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
    Langer CJ; Gadgeel SM; Borghaei H; Papadimitrakopoulou VA; Patnaik A; Powell SF; Gentzler RD; Martins RG; Stevenson JP; Jalal SI; Panwalkar A; Yang JC; Gubens M; Sequist LV; Awad MM; Fiore J; Ge Y; Raftopoulos H; Gandhi L;
    Lancet Oncol; 2016 Nov; 17(11):1497-1508. PubMed ID: 27745820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater.
    She L; Hu H; Liao M; Xia X; Shi Y; Yao L; Ding D; Zhu Y; Zeng S; Shen L; Huang J; Carbone DP
    Lung Cancer; 2019 Dec; 138():88-94. PubMed ID: 31655368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.
    O'Brien M; Paz-Ares L; Marreaud S; Dafni U; Oselin K; Havel L; Esteban E; Isla D; Martinez-Marti A; Faehling M; Tsuboi M; Lee JS; Nakagawa K; Yang J; Samkari A; Keller SM; Mauer M; Jha N; Stahel R; Besse B; Peters S;
    Lancet Oncol; 2022 Oct; 23(10):1274-1286. PubMed ID: 36108662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.